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A pathogenic tau fragment compromises
microtubules, disrupts insulin signaling and
induces the unfolded protein response
Tong Guo, Dina Dakkak, Teresa Rodriguez-Martin, Wendy Noble and Diane P. Hanger*
Abstract
Human tauopathies including Alzheimer’s disease, progressive supranuclear palsy and related disorders, are
characterized by deposition of pathological forms of tau, synaptic dysfunction and neuronal loss. We have previously
identified a pathogenic C-terminal tau fragment (Tau35) that is associated with human tauopathy. However, it is not
known how tau fragmentation affects critical molecular processes in cells and contributes to impaired physiological
function. Chinese hamster ovary (CHO) cells and new CHO cell lines stably expressing Tau35 or full-length human tau
were used to compare the effects of disease-associated tau cleavage on tau function and signaling pathways. Western
blots, microtubule-binding assays and immunofluorescence labeling were used to examine the effects of Tau35 on tau
function and on signaling pathways in CHO cells. We show that Tau35 undergoes aberrant phosphorylation when
expressed in cells. Although Tau35 contain the entire microtubule-binding region, the lack of the amino terminal half
of tau results in a marked reduction in microtubule binding and defective microtubule organization in cells. Notably,
Tau35 attenuates insulin-mediated activation of Akt and a selective inhibitory phosphorylation of glycogen synthase
kinase-3. Moreover, Tau35 activates ribosomal protein S6 kinase beta-1 signaling and the unfolded protein response,
leading to insulin resistance in cells. Tau35 has deleterious effects on signaling pathways that mediate pathological
changes and insulin resistance, suggesting a mechanism through which N-terminal cleavage of tau leads to the
development and progression of tau pathology in human tauopathy. Our findings highlight the importance of the N-
terminal region of tau for its normal physiological function. Furthermore, we show that pathogenic tau cleavage
induces tau phosphorylation, resulting in impaired microtubule binding, disruption of insulin signaling and activation
of the unfolded protein response. Since insulin resistance is a feature of several tauopathies, this work suggests new
potential targets for therapeutic intervention.
Keywords: Tau, Tauopathy, Microtubule binding, Akt, Glycogen synthase kinase-3, Insulin, Unfolded protein response
Background
Tauopathies are a heterogeneous group comprising de-
mentias and movement disorders, neuropathologically
characterized by prominent intracellular accumulations of
neurofibrillary tangles formed of tau in neurons and glia.
Accumulating evidence suggests that the conversion of
physiological tau to pathological tau plays a central role in
the development of tauopathy. In particular, abnormal
phosphorylation and fragmentation of tau have been pro-
posed as important post-translational modifications that
lead to pathogenic forms of tau [19]. In addition, a range
of inter-related cellular processes, including microtubule
disorganization [18, 55, 56], activation of the unfolded
protein response (UPR) [22, 34, 52], activation of the nu-
trient sensor mammalian target of rapamycin complex 1
(mTORC1) [9, 49], and deficiencies in insulin signaling
[41, 45], also promote cell dysfunction in tau-mediated
neurodegeneration. However, the cellular events linking
pathological changes in tau to cell dysfunction and the
pathogenesis of tauopathies are largely unknown.
We previously described a 35 kDa C-terminal tau frag-
ment (Tau35), lacking the N-terminus of tau but con-
taining all four microtubule-binding repeats (4R), that is
present in 4R tauopathies [53]. When expressed in
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transgenic mice, Tau35 induces several key features of
tauopathy, including accumulation of abnormally phos-
phorylated tau, dysregulation of glycogen synthase
kinase-3β (GSK3β) activity, progressive cognitive and
motor deficits, and loss of synaptic proteins [7]. Here we
have used a cell model to investigate the molecular
mechanisms that are affected by Tau35 expression. Our
findings suggest that aberrant tau cleavage may have a
key role in disrupting physiological signaling pathways
involved in the development of tauopathy.
Materials and methods
Plasmids
Plasmids encoding full-length 2N4R human tau (FL-tau)
or Tau35 were generated in pcDNA 3.1D/V5-His-TOPO
vector (Invitrogen), which carries a neomycin resistance
gene, a V5 epitope, a 6 ×His tag and the promoter from
cytomegalovirus. The original plasmid encoding FL-tau in
bacterial expression vector pRK172 was a kind gift from
Professor Michel Goedert (MRC Laboratory of Molecular
Biology, Cambridge, UK). cDNA sequences corresponding
to FL-tau and Tau35 were each inserted into the multiple
cloning site of the pcDNA 3.1D/V5-His-TOPO vector at
BamHI-XbaI [12]. Alpha-tubulin N-acetyltransferase 1
(αTAT1) plasmid [2] was a kind gift from Professor Jacek
Gaertig (University of Georgia, USA).
Cell maintenance and transfection
Mycoplasma negative Chinese hamster ovary (CHO)
cells, acquired from the European Collection of Authen-
ticated Cell Cultures, were grown at 37 °C with 5% CO2
in Ham’s F12 medium supplemented with 10% fetal bo-
vine serum, 2 mML-glutamine, 100 units/mL penicillin
and 100 μg/mL streptomycin (Thermo Fisher Scientific).
24 h before transfection, cells were plated at a density of
3.7 × 104 cells/cm2 in 6-well or 12-well plates. CHO cells
were transiently transfected with plasmids (2 μg plas-
mid/well for 6-well plate or 1 μg plasmid/well for
12-well plate) using jetPEI™ (Polyplus Transfection) ac-
cording to the manufacturer’s instructions. 24 or 48 h
after transfection, cells were processed for biochemical
assays, or fixed for immunocytochemistry.
Generation of stable CHO cell lines
CHO cells were transiently transfected with plasmids en-
coding either FL-tau or Tau35, as described above.
Non-transfected CHO cells were included as controls. 48
h after transfection the medium was replaced by Ham’s
F-12 medium as above, with the addition of 800 μg/mL
G418 (Santa Cruz). After selection, G418-resistant cells
were transferred to 145mm diameter dishes for clonal iso-
lation. Cell clusters were isolated using cloning cylinders
(Sigma) and transferred to 6-well plates for clonal expan-
sion. Further characterization of the G418-resistant cells
was undertaken using western blots to examine the stable
expression of tau protein and immunocytochemistry to
assess the homogeneity of the cell lines. Clonal cells
homogenously expressing 2N4R tau or Tau35, termed
CHO-FL and CHO-Tau35, respectively, were selected and
maintained in CHO cell growth medium without G418 at
37 °C in 5% CO2.
Cell treatments
24 h before treatment, CHO-FL, CHO-Tau35 and
untransfected CHO cells were seeded at a density of
3.7 × 104 cells/cm2. For insulin treatment, cells were
treated with 100 nM insulin (Sigma) for 30 min at 37 °C
before washing in phosphate-buffered saline (PBS, 137
mM NaCl, 2.7 mM KCl, 8 mM Na2HPO4, 2 mM
KH2PO4, pH 7.4). For LiCl treatment, cells were treated
with 5mM LiCl, or 5 mM NaCl (control) at 37 °C for 24
h, then washed with PBS. For thapsigargin treatment,
cells were treated with 800 nM thapsigargin for 5 h at
37 °C, then washed with PBS. After treatment, cells were
either scraped into ice-cold Tris-HCl buffer (50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 1 mM Na3VO4,
Complete protease inhibitor and Complete protease in-
hibitor cocktail [Roche]), lysed in 2× Laemmli sample
buffer and heated at 95 °C for 10 min for analysis on
western blots, or fixed for immunocytochemistry, as de-
scribed below.
In situ microtubule binding assay
In situ microtubule binding was assayed as described pre-
viously [40]. Briefly, 24 h before the experiment, CHO-FL
and CHO-Tau35 cells were plated (3.7 × 104 cells/cm2).
Cells were rinsed with warm PBS and scraped into warm
PIPES buffer (80mM piperazine-N,N′bis-2-ethanesulfonic
acid, pH 6.8, 1 mM guanosine-5′-triphosphate, 1 mM
MgCl2, 1 mM ethylene glycol-bis(2-aminoethyl)-N,N,N′,N
′-tetraacetic acid, 0.5% (w/v) Triton X-100 and 30% (v/v)
glycerol) containing Complete protease inhibitor (Roche),
20mM NaF, 0.5 μM okadaic acid (Merck), and 10 μM
taxol (Sigma). Cell lysates were centrifuged at 5000 g for
10min at ambient temperature, and an aliquot of the
supernatant was retained (total, T). The remaining
post-nuclear lysate was centrifuged at 100,000 g for 1 h at
37 °C. The supernatant (unbound fraction, U) was col-
lected, and the pellet (bound fraction, B) was rinsed twice
in PIPES buffer, pelleted at 100,000 g, and then resus-
pended in PIPES buffer. All fractions were suspended in
2× Laemmli sample buffer and heated at 95 °C for 10min
prior to analysis on western blots.
Western blots
Proteins in cell lysates and sub-cellular fractions were sepa-
rated on sodium dodecyl sulfate polyacrylamide gel electro-
phoresis. Electrophoresed proteins were transferred onto
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0.45 μm nitrocellulose membranes. Membranes were
blocked in Odyssey blocking buffer (Li-Cor Biosciences),
3% (w/v) dried skimmed milk in Tris-buffered saline/0.2%
(v/v) Tween 20 (TBST), or 5% (w/v) bovine serum albumin
in TBST for 30min at ambient temperature, then incubated
overnight at 4 °C in primary antibodies (Additional file 1:
Table S1). After washing, membranes were incubated for
60min at ambient temperature with the appropriate
fluorophore-conjugated secondary antibody (Alexa Fluor®
680 goat anti-mouse immunoglobulin G (IgG) or IRDye™
800 goat anti-rabbit IgG, Invitrogen). Antigens were visual-
ized using an Odyssey® infrared imaging system (Li-Cor
Biosciences). Images were analyzed using Li-Cor Image
Studio Lite software (Li-Cor Biosciences).
Immunocytochemistry
Cells on coverslips were washed 3 times in PBS, fixed for
10min in 4% (w/v) paraformaldehyde at 37 °C or in ice-cold
methanol at − 20 °C for 10min. Paraformaldehyde-fixed
cells were permeabilized using 0.25% (v/v) Triton X-100 for
10min at ambient temperature and washed in PBS. Follow-
ing incubation in blocking buffer (10% (v/v) fetal bovine
serum in PBS, pH 7.4) for 30min at ambient temperature.
Cells were incubated in primary antibody overnight at 4 °C,
followed by secondary antibody for 60min at ambient
temperature (Additional file 1: Table S1). Nuclei were
stained using Hoechst 33342 (5 μg/mL bisbenzimide in
PBS). Fluorescence microscopy was performed using a Leica
DM5000B fluorescence microscope equipped with a 63×/
1.25 immersion objective, and a digital camera (DFC360
FX, Leica) using Leica Application Suite Advanced Fluores-
cence Software (Leica). Images were processed and analyzed
using ImageJ software [44].
Quantification and statistical analysis
Quantitative analyses were performed using Microsoft
Excel and GraphPad Prism 7. Normality for individual
variables was determined by the Shapiro-Wilk test and
analyzed using Student’s unpaired t-test or one-way ana-
lysis of variance (ANOVA) followed by Tukey’s post-hoc
tests. Differences were considered statistically significant
when P < 0.05.
Results
Abnormal phosphorylation of Tau35
Tau phosphorylation plays an important role in regulat-
ing tau function and aberrant tau phosphorylation is
widely acknowledged as a key component of tauopathy
pathogenesis [20, 32]. Therefore, we examined the effect
of N-terminal cleavage on the phosphorylation status of
tau in cells. Lysates of CHO cells stably expressing either
full-length (2N4R isoform) human tau (CHO-FL) or
Tau35 (CHO-Tau35) were analyzed on western blots
using antibodies to phosphorylated tau (AT8, pSer202/
pThr205; AT180, pThr231; and PHF1, pSer396/pSer404)
and total tau (Fig. 1a). Antibodies recognizing phosphor-
ylated tau exhibited only modest (AT180, PHF1) or neg-
ligible (AT8) immunoreactivity with FL-tau, whereas all
tau antibodies recognized multiple Tau35 bands (Fig.
1a). The total tau antibody labelled predominant species
of 39 (doublet) and 35 kDa (Fig. 1a, arrowhead), together
with minor tau bands at 30 and 26 kDa, indicating the
presence of modified and degraded tau in CHO-Tau35
cells. All three phospho-dependent tau antibodies de-
tected the 39 and 35 kDa Tau35 species, although the 39
kDa doublet appeared as a single band with AT180, sug-
gesting that tau species derived from CHO-Tau35 cells
undergo phosphorylation at multiple residues. Tau spe-
cies smaller than 35 kDa were not labeled by PHF1, indi-
cating that Tau35 may be subject to C-terminal cleavage
in cells. Quantification of the blots showed that com-
pared to FL-tau, Tau35 phosphorylation increased ap-
proximately 2–3-fold at each of the epitopes examined
(Fig. 1b). These results demonstrate that N-terminally
cleaved tau is consistently and abnormally phosphory-
lated at several disease-relevant epitopes.
Disrupted microtubule organization in CHO-Tau35 cells
Since increased tau phosphorylation reduces micro-
tubule binding, we investigated the ability of Tau35 to
stabilize microtubules. CHO-FL and CHO-Tau35 cells
were fixed with methanol to remove soluble cytosolic
proteins and visualize the cytoskeleton by immunocyto-
chemistry. Expression of FL-tau induced formation of
microtubule bundles and robust co-localization of tau
with microtubules, neither of which were apparent in
CHO-Tau35 cells (Fig. 2a). Indeed, Tau35 immunoreac-
tivity markedly decreased after methanol fixation com-
pared to that in paraformaldehyde-fixed cells, which
preserves cytosolic proteins (Fig. 2a and Additional file 2:
Figure S1). Colocalization analyses of the FL-tau/
α-tubulin and Tau35/α-tubulin immunofluorescence in
the two cell lines demonstrated a significantly reduced
correlation of Tau35 with microtubules in CHO cells
(Fig. 2b, P < 0.01). Thus, unlike FL-tau, Tau35 localizes
predominantly in the cytosol, rather than binding to
and stabilizing microtubules. The reduced ability of
Tau35 to bind to microtubules was confirmed using an
in situ microtubule binding assay. FL-tau was present
in both microtubule-bound and unbound fractions,
with approximately 22% of total tau bound to microtu-
bules (Fig. 2 c, d). In contrast, approximately 6% of
Tau35 was present in the microtubule-bound fraction
in CHO-Tau35 cells. These results demonstrate a
significant reduction in the ability of Tau35 to bind to
microtubules, despite the presence of an intact
microtubule-binding domain.
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To determine the effect of Tau35 on microtubule stabil-
ity, CHO-FL, CHO-Tau35 and CHO cells were fixed with
paraformaldehyde and labelled with antibodies to total
and acetylated (Lys40) α-tubulin (Fig. 2e). Only a minor
proportion of the microtubule population was acetylated
in CHO-Tau35 and CHO cells (Fig. 2e), whereas expres-
sion of FL-tau resulted in the formation of an ordered
array of microtubules in CHO cells, and acetylated
α-tubulin largely overlapped with microtubules detected
by α-tubulin antibody (Fig. 2e). These findings indicate
that tubulin acetylation is elevated in CHO-FL cells, likely
due to increased microtubule stabilization. Acetylated
α-tubulin in CHO-Tau35 cells was located mainly in peri-
nuclear regions, coincident with the more intense
localization of α-tubulin, and with a similar distribution to
CHO cells (Fig. 2e). Analysis on western blots revealed in-
creased acetylated α-tubulin in CHO-FL cells compared
to CHO-Tau35 and CHO cells (Fig. 2f, g). Additionally,
CHO-Tau35 cells exhibited a rounder morphology than
the other two cell types (Fig. 2e), indicating a reduction in
the organization and extent of the microtubule cytoskel-
eton. Disruption of microtubules in CHO-Tau35 cells was
further evidenced by the finding that the area of
CHO-Tau35 cells was significantly less than CHO cells
(Fig. 2h). Taken together, these results show that, despite
containing all four microtubule-binding repeats, Tau35
has a reduced ability to bind to and stabilize microtubules.
Microtubule organization in CHO-Tau35 cells is not
restored by increasing tubulin acetylation or decreasing
tau phosphorylation
To determine whether enhancing α-tubulin acetylation
could reverse the Tau35-induced loss of microtubule
stabilization, cells were transiently transfected with a plas-
mid expressing α-tubulin N-acetyltransferase 1 (αTAT1)
to promote tubulin acetylation [5, 17, 37]. Expression of
αTAT1 was confirmed on western blots 48 h after trans-
fection (see Additional file 2: Figure S2). Methanol-fixed
cells labelled with antibodies to acetylated α-tubulin and
tau showed that exogenous expression of αTAT1 in-
creased α-tubulin acetylation in all three cell lines (Fig. 3a).
Notably, αTAT1 significantly enhanced the formation of
highly acetylated microtubule bundles that formed peri-
nuclear rings in CHO-FL cells (Fig. 3a, b). FL-tau
co-localized with microtubule rings following methanol
fixation (Fig. 3a). In contrast, increased α-tubulin acetyl-
ation resulted in little microtubule bundling and the ex-
tent of co-localization of acetylated α-tubulin with tau was
also limited in CHO-Tau35 cells (Fig. 3a), demonstrating
that the reduced microtubule-binding ability of Tau35 in
Fig. 1 Abnormal phosphorylation of Tau35. a Western blots of CHO-FL and CHO-Tau35 cell lysates probed with antibodies against total and
phosphorylated tau (AT8: pSer202/pThr205; AT180: pThr231; and PHF1: pSer396/pSer404). Molecular weight markers (kDa) are shown on the left.
b Graphs show the ratio of phosphorylated/total tau in CHO-FL and CHO-Tau35 cells, standardized to CHO-FL cell values (100%). Values represent
mean ± S.E.M., n = 3–4. Student’s t-test, **P < 0.01
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not restored by increasing tubulin acetylation. Similar to
CHO-Tau35 cells, increasing α-tubulin acetylation in
CHO cells also resulted in only limited microtubule bund-
ling in the absence of tau (Fig. 3a). These results indicate
that in contrast to FL-tau, Tau35 lacks the ability to pro-
mote microtubule bundling in cells.
Phosphorylation of tau by kinases including GSK3,
negatively affects interactions between tau and microtu-
bules [10, 15, 46]. To investigate whether the decreased
microtubule binding ability of Tau35 is due to its in-
creased phosphorylation state (Fig. 1), CHO-Tau35 cells
were treated with 5 mM LiCl for 24 h to inhibit
GSK3-mediated tau phosphorylation. Western blots of
CHO-Tau35 cell lysates probed with PHF1 antibody
confirmed that LiCl reduced Tau35 phosphorylation by
approximately 75% at residues Ser396/Ser404 and
caused a shift of tau species to lower apparent molecular
weight, confirming the highly phosphorylated nature of
Tau35 (see Additional file: Figure S3). Despite the clear
reduction in Tau35 phosphorylation, LiCl did not affect
the proportion of either microtubule-bound Tau35, or
polymerized α-tubulin in CHO-Tau35 cells (Fig. 3c, d).
Therefore, decreasing the phosphorylation state of
Tau35 appears to be insufficient to restore its interaction
with microtubules. Hence, increased phosphorylation of
Tau35 appears unlikely to be a major factor involved in
its inability to bind to microtubules in cells.
Divergent effects of FL-tau and Tau35 on insulin signaling
via Akt/GSK3
The increased phosphorylation of Tau35 in cells suggests
altered activity of tau kinases. Therefore, we determined
the activity of the candidate tau kinase GSK3, and its up-
stream inhibitor Akt (protein kinase B), in CHO-FL,
CHO-Tau35 and CHO cells. CHO-FL cells exhibited en-
hanced total and phosphorylated Akt, indicative of in-
creased activity, in comparison to CHO-Tau35 and CHO
cells (Fig. 4a, b). Correspondingly, inhibitory phosphoryl-
ation of GSK3β at Ser9 was augmented in CHO-FL cells
compared to CHO-Tau35 and CHO cells (Fig. 4b). We
also detected reduced inhibitory phosphorylation of
GSK3β, indicating activation of GSK3β in the presence of
Tau35 (Fig. 4a, b). The total amount and phosphorylation
state of GSK3α was comparable in all three cell lines (Fig.
4a, b). These data indicate that FL-tau and Tau35 exert
differing effects on the Akt/GSK3 pathway, with FL-tau
promoting the steady-state amount of Akt and also in-
creasing its activation state, thereby inactivating GSK3β.
In contrast, Tau35 lacks the capacity to activate Akt and
reduce the activity of GSK3β, suggesting a potential mech-
anism for the increased phosphorylation of Tau35.
Since the Akt/GSK3 pathway is a critical mediator of
the insulin signaling pathway, we investigated the effects
of FL-tau and Tau35 on insulin responsiveness in CHO
cells. Lysates from CHO-FL, CHO-Tau35 and CHO cells
treated with 100 nM insulin for 30min were analyzed on
western blots (Fig. 4c). Insulin significantly increased Akt
phosphorylation in all cell lines (Fig. 4c, d). CHO-FL cells
exhibited the greatest (4.4-fold) Akt activation, whereas in
both CHO-Tau35 cells and CHO cells, insulin resulted in
approximately 3.7-fold activation of Akt. In line with Akt
activation, insulin promoted inhibitory phosphorylation of
GSK3α and GSK3β in cell lines (Fig. 4d). As previously
observed with Akt activation, insulin-mediated inhibitory
phosphorylation of GSK3α and GSK3β was most affected
in CHO-FL cells. In contrast, inhibitory phosphorylation
of GSK3β in response to insulin was significantly lower in
CHO-Tau35 cells than in CHO-FL and CHO cells.
Insulin-mediated GSK3α activation was similar in both
CHO-Tau35 and CHO cells, whereas it was significantly
elevated in CHO-FL cells. These findings suggest that,
compared to CHO cells expressing FL-tau, Tau35 impairs
insulin responsiveness, repressing both Akt activation and
inhibitory phosphorylation of GSK3, particularly GSK3β.
Tau35 impairs insulin signaling through activation of
mTORC1/S6K1 signaling
Repression of insulin signaling is associated with activa-
tion of mTORC1 and its downstream effector ribosomal
protein S6 kinase β-1 (S6K1), which is phosphorylated
(See figure on previous page.)
Fig. 2 Reduced microtubule organization in CHO-Tau35 cells. a Immunofluorescence of methanol-fixed CHO-FL and CHO-Tau35 cells, labeled
with antibodies to α-tubulin (red), tau (green) and Hoescht 33,342 (blue, nuclei). Scale bar = 20 μm. b Graph showing the correlation (Pearson’s) of
tau colocalization with microtubules in CHO-FL and CHO-Tau35 cells. Values represent mean ± S.E.M, n = 80 cells from 3 independent
experiments, Student’s t-test, **P < 0.01. c Western blots of total cell lysate (T), unbound (U), and microtubule-bound (B) fractions of CHO-FL and
CHO-Tau35 cells probed with antibody to total tau. Molecular weight markers (kDa) are shown on the left. d Graph showing the ratio of tau in
the microtubule (MT)-bound fraction relative to total tau in CHO-FL and CHO-Tau35 cell lysates. Values represent mean ± S.E.M., n = 3, Student’s t-
test, **P < 0.01. e Immunofluorescence of paraformaldehyde-fixed CHO-FL, CHO-Tau35, and untransfected CHO cells labelled with antibodies to
α-tubulin (green), acetylated α-tubulin (red) and Hoechst 33342 (blue). Scale bar = 20 μm. f Western blots of CHO-FL, CHO-Tau35 and CHO cell
lysates probed with antibodies recognizing acetylated and total α-tubulin. Molecular weight markers (kDa) are shown on the left. g Graph
showing the ratio of acetylated/total α-tubulin in CHO-FL and CHO-Tau35 cells, relative to CHO cells (100%). Values represent mean ± S.E.M., n = 4,
one-way ANOVA, *P < 0.05, **P < 0.01. h Graph showing the areas of CHO-FL, CHO-Tau35 and CHO cells, mean ± S.E.M. A minimum of 50 cells
were measured for each cell line. One-way ANOVA, *P < 0.05
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and activated by mTORC1-mediated phosphorylation
at Thr389. mTORC1/S6K1 signaling negatively regu-
lates insulin signaling through inhibitory phosphoryl-
ation of insulin receptor substrate 1 (IRS1) [35]. When
assessed on western blots, S6K1 phosphorylation in
CHO-Tau35 cells was approximately 3-fold higher than
that in CHO cells, whereas it was unchanged in
CHO-FL cells (Fig. 5a, b), indicating a selective
upregulation of S6K1 activity by Tau35. Phosphoryl-
ation of the S6K1 substrate, S6 ribosomal protein, also
increased approximately 3-fold in CHO-Tau35 cells and
remained unchanged in CHO-FL cells (Fig. 5a, b).
These data suggest that mTORC1/S6K1 signaling is sig-
nificantly upregulated in CHO-Tau35 cells, and this ap-
pears to be a gain of function of Tau35 that
differentiates it from FL-tau.
Fig. 3 Microtubule organization in CHO-Tau35 cells is not restored by increasing tubulin acetylation or decreasing tau phosphorylation.
a CHO-FL, CHO-Tau35 and CHO cells were transiently transfected with a plasmid expressing α-tubulin N-acetyltransferase 1 (αTAT1, +) or
without plasmid (−). Panels show immunofluorescence of methanol-fixed cells labelled with antibodies to acetylated α-tubulin (red), tau
(green), and Hoechst 33342 (blue, nuclei). Scale bar = 20 μm. b Graph showing the percentage of cells exhibiting microtubule (MT) bundles in
CHO-FL, CHO-Tau35 and CHO cells in the presence (+) or absence (−) of αTAT1. Values represent mean ± S.E.M. A minimum of 150 cells were
counted for each transfection condition; two-way ANOVA, **P < 0.01; ***P < 0.001. c Western blots of tau and α-tubulin in total cell lysate (T),
unbound (U) and MT-bound (B) fractions of CHO-Tau35 cells treated with 5 mM LiCl (+) or 5 mM NaCl (−) for 24 h and probed with antibodies
to tau or α-tubulin. d Graphs show the amount of tau present in the MT-bound fractions, relative to total Tau35 (left), and the amount of
polymerized α-tubulin relative to total α-tubulin (right) in CHO-Tau35 cells, following exposure to NaCl (control) or LiCl. Values represent
mean ± S.E.M., n = 3. Student’s t-test, *P < 0.05, **P < 0.01
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Amongst the inhibitory target phosphorylation sites on
human IRS1, Ser636/Ser639 and Ser1101 (equivalent to ro-
dent Ser632/Ser635 and Ser1097) are phosphorylated fol-
lowing mTORC1/S6K1 activation [50, 51]. Enhanced
activation of S6K1 in CHO-Tau35 cells promoted Ser636/
Ser639 phosphorylation of IRS1, compared to both CHO
and CHO-FL cells (Fig. 5c, d). S6K1 also increased IRS1
Ser1101 phosphorylation in CHO-Tau35 cells compared to
CHO-FL cells (Fig. 5c, d). These results indicate that the
disrupted insulin signaling apparent in CHO-Tau35 cells
may be caused by mTORC1/S6K1-mediated inhibitory
phosphorylation of IRS1, which does not occur with FL-tau.
Tau35 induces the unfolded protein response
Since mTORC1 activation can induce the UPR, we inves-
tigated the status of the UPR in CHO cells expressing
FL-tau and Tau35. Activation of PRKR-like endoplasmic
reticulum kinase (PERK) is observed in CHO-Tau35 cells,
as demonstrated by increases in both total and phosphory-
lated PERK (Fig. 6a, b). In marked contrast, PERK activa-
tion was negligible in CHO-FL and CHO cells (Fig. 6a, b).
PERK activation leads to phosphorylation of eukaryotic
translation initiation factor 2α (eIF2α), which was also in-
creased in CHO-Tau35 cells (Fig. 6a, b). These results in-
dicate that Tau35, but not FL-tau, selectively activates the
PERK branch of the UPR.
In parallel to PERK activation, we also found an enrich-
ment of the 36 kDa fragment of activating transcription
factor 6α (ATF6α-p36) in CHO-Tau35 cells (Fig. 6c, d), in-
dicating activation of the ATF6α branch of the UPR [23,
28, 36]. Notably, cleavage of ATF6α was significantly re-
duced in CHO-FL cells, indicating potential suppression
of this branch of the UPR by FL-tau. We were unable to
detect phosphorylation (activation) of inositol-requiring
enzyme 1α (IRE1α) in any of the three cell lines and there
were no differences in the total amount of IRE1α present
(Fig. 6c, d), suggesting that this branch of the UPR is not
activated by either Tau35 or FL-tau.
CCAAT-enhancer-binding protein homologous pro-
tein (CHOP) is an integrated transcriptional target that
lies downstream of both the PERK and ATF6 branches
of the UPR. Western blots of CHOP showed a corre-
sponding increase in CHO-Tau35 cells, whereas the
amount of CHOP in CHO-FL cells was unchanged (Fig.
6c, d). Furthermore, induction of endoplasmic reticulum
(ER) stress with thapsigargin, resulted in sensitized acti-
vation of both PERK and IRE1α in CHO-Tau35 cells
compared with both CHO-FL and CHO cells (see Add-
itional file 2: Figure S4). These results suggest that
CHO-Tau35 cells are more sensitive to ER stress, which
is widely seen in cells with chronic mTORC1 activation
[13, 24]. Taken together, these results support the view
that expression of Tau35 but not FL-tau, selectively acti-
vates the PERK and ATF6α branches of the UPR, with-
out affecting IRE1α signaling.
Discussion
We previously identified a 35 kDa C-terminal tau frag-
ment termed Tau35 (residues 187–441 of FL-tau), in 4R
human tauopathy brain [53]. Tau35 is generated by
cleavage of human tau, resulting in a tau fragment that
lacks the N-terminal domain and part of the proline-rich
domain, but contains all four microtubule-binding re-
peats and an intact C-terminus (Fig. 6e). Minimal ex-
pression of Tau35 in transgenic mice causes several key
features of human tauopathy [7]. Here we investigated
the molecular mechanisms underlying the development
of disease-related phenotypes using cells stably express-
ing Tau35.
Tau phosphorylation plays a key role in regulating tau
localization and function, and aberrant phosphorylation
of tau reduces its ability to bind to microtubules [16,
46]. When expressed in CHO cells, Tau35 displayed ele-
vated phosphorylation at several epitopes associated with
the development of human tauopathy, in which aggre-
gates of highly phosphorylated and fragmented tau are
present [4, 53], highlighting the relevance of this Tau35
cell model to human tauopathy.
Tau35 has a reduced ability to bind to microtubules,
despite the presence of all four microtubule binding re-
peats (residues 244–401 of human FL-tau) and an intact
C-terminus. Moreover, reducing Tau35 phosphorylation
using lithium did not increase the interaction between
Tau35 and microtubules, suggesting that the reduced
binding was not due to increased phosphorylation of
Tau35 in CHO cells. Our findings therefore support the
view that the reduced microtubule binding ability of
Tau35 is due to the absence of amino acid sequences
(See figure on previous page.)
Fig. 4 Differing effects of FL-tau and Tau35 on Akt/GSK3 signaling. a Western blots of CHO-FL, CHO-Tau35 and untransfected CHO cell lysates
probed with antibodies against phosphorylated and total Akt, phosphorylated and total GSK3α/β, and glyceraldehyde 3-phosphate
dehydrogenase (GAPDH). Molecular weight markers (kDa) are shown on the left. b Graphs show the percentage of phosphorylated/total Akt and
phosphorylated/total GSK3α/β, relative to untransfected CHO cells (100%). Values represent mean ± S.E.M., n = 4, one-way ANOVA, *P < 0.05, **P <
0.01. c Western blots of lysates of CHO-FL, CHO-Tau35 and untransfected CHO cell lysates treated with (+) or without (−) 100 nM insulin for 30
min. Blots were probed with antibodies against phosphorylated and total Akt, phosphorylated and total GSK3α/β, and GAPDH. Molecular weight
markers (kDa) are shown on the left. d Graphs show phosphorylated/total Akt, phosphorylated/total GSK3β, and phosphorylated/total GSK3α.
Data are displayed as percentage change compared to the untreated CHO cells (100%). Values represent mean ± S.E.M., n = 6, two-way ANOVA,
**P < 0.01, ***P < 0.001
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present in the N-terminal half of tau. These results par-
allel those of others showing that N-terminally cleaved
tau species display altered interactions with microtu-
bules [11, 31, 57] and indicate that the N-terminal re-
gion of tau is important for its association with
microtubules. It is possible that an extended region of
tau, encompassing domains outside the microtubule
binding and flanking regions, may be required in order
to facilitate microtubule binding and stabilization since
truncated forms of tau corresponding to residues 1–255
and 256–441 also exhibit reduced abilities to polymerize
microtubules [57]. Notably, unlike Tau35, a different tau
Fig. 5 mTORC1/S6K1-mediated IRS1 inhibition by Tau35. a Western blot analysis of downstream effectors of mTORC1. CHO-FL, CHO-Tau35 and
untransfected CHO cell lysates probed with antibodies to phosphorylated/total ribosomal protein S6 kinase beta-1 (S6K1) and phosphorylated/
total S6 ribosomal protein (S6). Molecular weight markers (kDa) are shown on the left. b Graphs show the relative amounts of phosphorylated/
total S6K1 and phosphorylated/total S6. Data are displayed as percentage change compared to untransfected CHO cells (100%). c Western blot
analysis of IRS1 activity. CHO-FL, CHO-Tau35 and untransfected CHO cell lysates probed with antibodies to phosphorylated/total insulin receptor
substrate 1 (IRS1), and GAPDH. Molecular weight markers (kDa) are shown on the left. d Graphs show the relative amounts of phosphorylated
(Ser636/Ser639)/total IRS1, and phosphorylated (Ser1101)/total IRS1. Data are displayed as percentage changes compared to untransfected CHO
cells (100%). Values represent mean ± S.E.M., n = 4–6, one-way ANOVA, *P < 0.05, **P < 0.01
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Fig. 6 (See legend on next page.)
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fragment comprising residues 124–441, displays an in-
creased ability to bind and stabilize microtubules com-
pared to FL-tau [11]. Taken together, these findings
indicate that a sequence of amino acids located between
residues 124–186 of FL-tau may be critical for its inter-
action with microtubules.
Tau35 was unable to induce significant microtubule
bundling, even after enhancing tubulin acetylation, con-
sistent with the proposal that microtubule bundling is
promoted by complementary intermolecular dimerization
between the N-terminus and the proline-rich domains of
tau [42]. Such a model provides an explanation for this
loss of function of Tau35, since it lacks N-terminal tau
residues, which may be required for regulating micro-
tubule organization.
The adverse effects of Tau35 on insulin signaling also
distinguish it from FL-tau. In particular, FL-tau interacts
with and reduces the activity of phosphatase and tensin
homologue on chromosome 10 (PTEN), thereby promot-
ing Akt activation [30]. Notably, knocking out tau also re-
duces Akt activity and impairs the hippocampal response
to insulin [30]. Our finding of increased Akt activity in the
presence of FL-tau supports this view, whereas cleavage of
tau to generate Tau35 could potentially prevent or perturb
its interaction with PTEN, attenuating Akt activation and
resulting in enhanced GSK3 activity. Defective inactivation
of GSK3β in CHO-Tau35 cells was also observed in
CHO-Tau35 cells exposed to insulin. Whereas FL-tau fa-
cilitates insulin signaling, attenuated Akt phosphorylation
in response to insulin in CHO-Tau35 cells suggests the in-
duction of insulin resistance.
We also identified activation of mTORC1/SK61 signal-
ing as a potential mediator of the adverse impact of Tau35
on insulin signaling in CHO-Tau35 cells, resulting in IRS1
phosphorylation. Altered IRS1 phosphorylation and
insulin resistance have been reported in several tauopa-
thies, including Alzheimer’s disease, progressive supra-
nuclear palsy and corticobasal degeneration [54].
However, the mechanisms leading from pathological
changes in tau, to insulin resistance in human tauopathy
are not well understood. Notably, upregulation of
mTORC1 activity increases both tau phosphorylation and
tau pathology [9]. Our data therefore support the view
that Tau35 may trigger inhibitory phosphorylation of IRS1
through activation of mTORC1/S6K1 signaling, which in
turn exacerbates phosphorylation of Tau35.
Intriguingly, we identified chronic activation of the
PERK and ATF6 branches of the UPR induced by Tau35,
which has also been found in human tauopathy [8, 39,
47]. Activation of the PERK and ATF6α branches of the
UPR lead to expression of pro-apoptotic factor CHOP,
which is also elevated by Tau35 [21, 25]. Interestingly, the
IRE1α branch of the UPR does not appear to be affected,
indicating selectivity in Tau35-induced UPR activation.
Prolonged PERK signaling impairs cell proliferation and
promotes apoptosis, whereas IRE1α signaling enhances
cell proliferation [27]. Such divergence in the activation of
PERK and IRE1α may be indicative of persistent ER stress
[26, 27] in CHO-Tau35 cells, which ultimately results in
an imbalance between detrimental and protective effects
of UPR activation. It has been suggested that PERK can fa-
cilitate the translation and activation of ATF6α [48], thus,
it will be of interest to examine whether Tau35 directly
triggers ATF6α activation, or whether this is the result of
prior PERK activation. Tau35 also renders CHO cells
more susceptible to thapsigargin-mediated activation of
the UPR, which has been linked to accumulation of abnor-
mally phosphorylated tau [1, 29]. The mechanisms that
contribute to UPR activation in tauopathy are unclear. It
has been proposed that soluble tau oligomers are the
(See figure on previous page.)
Fig. 6 Induction of the unfolded protein response in CHO-Tau35 cells. a Western blot analysis of components of the PERK branch of the UPR.
CHO-FL, CHO-Tau35 and CHO cell lysates were probed with antibodies to phosphorylated/total PERK, phosphorylated/total eIF2α, and GAPDH.
Molecular weight markers (kDa) are shown on the left. b Graphs show the relative amounts of phosphorylated/total PERK, total PERK/GAPDH, and
phosphorylated/total eIF2α. Data are displayed as percentage changes compared to untransfected CHO cells (100%). Values represent mean ±
S.E.M., n = 4–6, one-way ANOVA, *P < 0.05, **P < 0.01. c Western blots of ATF6, IRE1 and CHOP components of the UPR. CHO-FL, CHO-Tau35 and
CHO cell lysates were probed with antibodies to cleaved ATF6α (36 kDa), phosphorylated/total IRE1α, CHOP and β-actin. d Graphs show the
relative amounts of cleaved ATF6α (36 kDa)/β-actin, total IRE1α/GAPDH, and total CHOP/β-actin. Data are displayed as percentage changes
compared to untransfected CHO cells (100%). Values represent mean ± S.E.M., n = 4–6, one-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001. e The
major domains and amino acid numbering of human FL-tau and Tau35 are illustrated (upper panel) showing the projection (amino acids 1–198)
and microtubule binding (amino acids 199–441) domains of FL-tau. N1 and N2 correspond to the alternatively spliced amino acid sequences
encoded by exons 2 and 3, respectively. The proline-rich domain (PRD, amino acids 151–243) is followed by the microtubule binding repeat
region (R1-R4, amino acids 244–368), including the alternatively spliced sequence encoded by exon 10 (R2). The scheme in the lower panel
indicates potential mechanisms by which Tau35 may be involved in the development of tauopathy. Tau35 has a reduced ability to bind to and
stabilize microtubules, which compromises microtubule organization (loss of function). Potential gains of toxic function by Tau35 include
triggering the activation of multiple branches of the unfolded protein response (UPR) and an increase in CHOP, which may lead to the
downstream suppression of Akt activity. The accumulation of unfolded Tau35 results in activation of GSK3β through perturbation of Akt signaling
and increased tau phosphorylation. In parallel, Tau35 expression activates mTORC1-S6K1 signaling, resulting in inhibitory phosphorylation of IRS1
and suppression of Akt, rendering CHO-Tau35 cells less responsive to insulin
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driving force behind tau-induced ER stress [1] and these
could impair ER-associated degradation, resulting in UPR
activation [14, 38].
Activation of both mTORC1/S6K1 and UPR signaling
are associated with neurodegenerative disease [3] and
importantly, crosstalk between these two pathways is in-
creasingly recognised. Such interactions include
ATF6α-mediated upregulation of mTORC1 [43] and
UPR activation contributing to insulin resistance [6, 33].
Given the inter-dependence of these two pathways, sup-
pressed insulin signaling may be the synergistic conse-
quence of activation of both the UPR and mTORC1/
S6K1 pathways in CHO-Tau35 cells and potentially also
in human tauopathy brain.
Conclusions
In summary, we propose a mechanism in which
N-terminal cleavage of tau leads to the development and
progression of tau pathology, compromising the ability
of tau to facilitate microtubule organization, disrupting
microtubule integrity, microtubule assembly, and bind-
ing to microtubules (Fig. 6e). Moreover, Tau35 triggers
activation of the mTORC1-S6K1 and UPR pathways,
undermining insulin signaling through inhibitory phos-
phorylation of IRS1. Moreover, our findings highlight
the importance of the N-terminal half of tau for its
physiological function since lack of this region disrupts
insulin-Akt-GSK3β signaling, fuels tau phosphorylation
and increases susceptibility to ER stress. Consequently,
accumulation of potentially pathogenic tau fragments
such as Tau35, results in a perpetuating cycle of tau
pathology that disrupts cellular function and leads to the
demise of neurons in the tauopathies. Thus, cleavage of
tau may be a key event linking tau pathology to disrup-
tions in insulin sensitivity and aberrant cell signaling.
Our findings provide several potential targets for thera-
peutic intervention in the tauopathies and demonstrate
the utility of the CHO-Tau35 cell model as a tool for
drug discovery.
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Additional file 1: Table S1. Antibodies used for western blots and
immunohistochemistry. (PDF 79 kb)
Additional file 2: Figure S1. Expression of tau in paraformaldehyde-
fixed CHO-FL and CHO-Tau35 cells. Immunofluorescence of
paraformaldehyde-fixed CHO-FL, CHO-Tau35, and untransfected CHO cells
labeled with antibodies to α-tubulin (red), total tau (green), and Hoechst
33342 (blue). Scale bar = 20 μm. Figure S2. Validation of exogenous ex-
pression of α-tubulin N-acetyltransferase 1 (αTAT1). Western blots of
CHO-FL, CHO-Tau35 and CHO cell lysates transfected with (+) or without
(−) a plasmid encoding αTAT1. Blots were probed with antibodies recog-
nizing αTAT1, acetylated and total α-tubulin. Molecular weight markers
(kDa) are shown on the left. Figure S3. LiCl treatment reduces phosphor-
ylation of Tau35. Western blots of CHO-Tau35 cell lysates treated with 5
mM NaCl (−) or 5 mM LiCl (+) for 24 h and probed with antibodies
against total and phosphorylated (PHF1) tau. Graphs show the ratio of
phosphorylated/total tau in the presence of NaCl (control) or LiCl. Values
represent mean ± S.E.M., n = 3. Student’s t-test, *P < 0.05. Figure S4.
Thapsigargin-induced UPR activation in CHO-FL, CHO-Tau35 and CHO
cells. a Western blots of CHO-FL, CHO-Tau35 and CHO cell lysates treated
with (+) or without (−) 800 nM thapsigargin (TG) for 5 h. Blots were
probed with antibodies recognizing phosphorylated/total PERK, phos-
phorylated/total IRE1α, and GAPDH. Molecular weight markers (kDa) are
shown on the left. b Graphs show the relative amounts of phosphory-
lated/total PERK, and phosphorylated/total IRE1α after thapsigargin treat-
ment. Data are displayed as percentage change compared to TG-treated
CHO cells (100%). Values represent mean ± S.E.M., n = 4, two-way ANOVA,
*P < 0.05, **P < 0.01. (PDF 332 kb)
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